Functional interactions between glutamate and dopamine in the rat striatum.
The functional role of NMDA receptors in a spontaneous (locomotion) and a conditioned behaviour (reaction-time task) known to preferentially involve dopamine transmission in the ventral or the dorsal part of the striatum, respectively, was studied in the rat. The non-competitive NMDA receptor antagonist MK-801 systemically injected produced a dose-dependent increase in locomotor activity and impaired the performance of the animals trained to release a lever after a visual stimulus within a time limit by increasing the number of anticipatory errors (lever releases occurring before the stimulus onset). Similar behavioural changes were obtained after bilateral striatal microinjections of the competitive NMDA-antagonist APV into the ventral or dorsal striatum, respectively, suggesting that MK-801-induced behavioral effects after systemic injection might be mediated through a blockade of EAA transmission within the striatum. Dopamine injected in the same striatal locations induced effects similar to APV on locomotion and reaction-time performance, in agreement with the proposal for a functional antagonism between the glutamatergic and the dopaminergic transmission at striatal level. The conjoint administration of APV and dopamine directly into the striatum did not alter the behavioural effect induced by each compound injected alone showing that these effects are not additive. This latter observation actually suggests the occurrence of a functional interaction between the two neuronal systems probably acting on a common striatal target relaying dopaminergic and glutamatergic antagonistic influences on locomotion and conditioned motor behaviours.
Amalric
M
M
Laboratoire de Neurobiologie Cellulaire et Fonctionnelle, CNRS, Marseille, France.
Ouagazzal
A
A
Baunez
C
C
Nieoullon
A
A
D015763:2-Amino-5-phosphonovalerate / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D003213:Conditioning, Psychological; D003342:Corpus Striatum / Q000187:drug effects / Q000502:physiology*; D016291:Dizocilpine Maleate / Q000008:administration & dosage / Q000494:pharmacology; D004298:Dopamine / Q000008:administration & dosage / Q000378:metabolism* / Q000494:pharmacology; D018698:Glutamic Acid / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D008845:Microinjections; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors / Q000502:physiology
D016194:Receptors, N-Methyl-D-Aspartate; D018698:Glutamic Acid; D016291:Dizocilpine Maleate; D015763:2-Amino-5-phosphonovalerate; D004298:Dopamine